FDA Sentinel Initiative Debate: How Specific Should Safety Info Be?
This article was originally published in The Gray Sheet
Executive Summary
Recent comments submitted to FDA betray stakeholder tensions surrounding what information should be made accessible, and to whom, as part of a planned medical products safety surveillance program